Literature DB >> 629327

Inhibition of human neutrophil oxidative metabolism and degranulation in vitro by nitroblue tetrazolium and vitamin E.

J E Repine, G Rao, G D Beall, J G White.   

Abstract

The effect of a mixture of nitroblue tetrazolium (NBT) and vitamin E on the metabolism and ultrastructure of polymorphonuclear leukocytes (PMN) from normal subjects or patients with chronic granulomatous disease (CGD) was determined in vitro. Increasing concentrations of NBT and vitamin E progressively decreased rates of oxygen consumption and 1-14C-glucose oxidation by normal PMN stimulated with particulates to a degree that exceeded either agent alone. NBT-vitamin-E also inhibited vacuole formation and the cytochemical release of myeloperoxidase-positive granules. The depressed oxidative metabolism and degranulation of NBT-vitamin-E-treated control PMN closely approximated the blunted responses of CGD PMN which were similar alone or in the presence of NBT-vitamin-E. In contrast to these effects, the highest concentration of NBT-vitamin-E used in the study did not damage, decrease rates of unstimulated oxidative metabolism of, or impair ingestion of particulates by control or CGD PMN. NBT and vitamin E impose a state on normal PMN which is remarkably similar to that observed in PMN from patients with CGD.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 629327      PMCID: PMC2018253     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  The role of superoxide anion and hydrogen peroxide in phagocytosis-associated oxidative metabolic reactions.

Authors:  R L Baehner; S K Murrmann; J Davis; R B Johnston
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

2.  Evidence for hydroxyl radical production by human neutrophils.

Authors:  A I Tauber; B M Babior
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

3.  Effects of nitroblue tetrazolium and vitamin E on platelet ultrastructure, aggregation, and secretion.

Authors:  J G White; G H Rao; J M Gerrard
Journal:  Am J Pathol       Date:  1977-08       Impact factor: 4.307

4.  Autooxidation as a basis for altered function by polymorphonuclear leukocytes.

Authors:  R L Baehner; L A Boxer; J M Allen; J Davis
Journal:  Blood       Date:  1977-08       Impact factor: 22.113

5.  The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes.

Authors:  R L Baehner; L A Boxer; J Davis
Journal:  Blood       Date:  1976-08       Impact factor: 22.113

6.  The particulate superoxide-forming system from human neutrophils. Properties of the system and further evidence supporting its participation in the respiratory burst.

Authors:  B M Babior; J T Curnutte; B J McMurrich
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

7.  Laboratory models of chronic granulomatous disease.

Authors:  B Holmes; R A Good
Journal:  J Reticuloendothel Soc       Date:  1972-08

8.  Defect in pyridine nucleotide dependent superoxide production by a particulate fraction from the cranulocytes of patients with chronic granulomatous disease.

Authors:  J T Curnutte; R S Kipnes; B M Babior
Journal:  N Engl J Med       Date:  1975-09-25       Impact factor: 91.245

9.  Influence of a deficiency of the second component of complement on the bactericidal activity of neutrophils in vitro.

Authors:  J E Repine; C C Clawson; P S Friend
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Hydrogen peroxide production in chronic granulomatous disease. A cytochemical study of reduced pyridine nucleotide oxidases.

Authors:  R T Briggs; M L Karnovsky; M J Karnovsky
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

View more
  1 in total

Review 1.  Cell biology of leukocyte abnormalities--membrane and cytoskeletal function in normal and defective cells. A review.

Authors:  J M Oliver
Journal:  Am J Pathol       Date:  1978-10       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.